Cancer Genetics, Inc (CGIX): John Pappajohn , director 10% owner of Cancer Genetics, Inc purchased 317,820 shares on May 25, 2016. The Insider buying transaction was reported by the company on Jul 19, 2016 to the Securities and Exchange Commission. The shares were purchased at $0.00 per share for a total value of $0.00 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on May 26, 2016, John Pappajohn (director 10% owner) purchased 317,820 shares at $0.00 per share price.On Mar 18, 2016, Howard Mcleod (director) purchased 1,000 shares at $2.71 per share price.Also, On Mar 17, 2016, Panna Sharma (CEO) purchased 1,500 shares at $2.59 per share price.On Mar 17, 2016, Michael J. Welsh (director) purchased 40 shares at $2.42 per share price.
Cancer Genetics Inc: On Monday, Jul 18, 2016 heightened volatility was witnessed in Cancer Genetics Inc which led to swings in the share price. The shares opened for trading at $2.1 and hit $2.23 on the upside , eventually ending the session at $2.08, with a gain of 0.73% or 0.015 points. The heightened volatility saw the trading volume jump to 1,56,508 shares. The 52-week high of the share price is $12.248 and the company has a market cap of $28 M . The 52-week low of the share price is at $1.82.
Cancer Genetics Inc. is an oncology diagnostics company focused on developing commercializing and providing DNA-based tests and services. The business is based on demand for DNA-based diagnostic services from three main sectors including cancer centers and hospitals biotechnology and biopharmaceutical companies and the research community. Its clinical offerings include its portfolio of proprietary tests targeting hematological urogenital and HPV-associated cancers in conjunction with ancillary non-proprietary tests. Biopharma services include laboratory and testing services performed for biopharmaceutical companies engaged in clinical trials. Discovery services provide the tools and testing methods for companies and researchers seeking to identify new DNA-based biomarkers for disease.